Cargando…
EGFR Inhibition in a Pretreated Sacral Chordoma: A Role for Erlotinib? Case Report and a Brief Review of Literature
We describe the case of a 69-year old male with an EGFR- positive Imatinib refractory sacral chordoma with synchronous lung metastases, treated with erlotinib, a first-generation EGFR inhibitor. After disease progression following first-line Imatinib and a combination therapy with everolimus plus me...
Autores principales: | Trapani, D., Conforti, F., De Pas, T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Università di Salerno
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5536160/ https://www.ncbi.nlm.nih.gov/pubmed/28775967 |
Ejemplares similares
-
Partial response to erlotinib in a patient with imatinib-refractory sacral chordoma
por: Verma, Saurav, et al.
Publicado: (2020) -
Recurrent Sacral Chordoma: A Case Report
por: Shrestha, Abhash, et al.
Publicado: (2020) -
Erlotinib Inhibits Growth of a Patient-Derived Chordoma Xenograft
por: Siu, I-Mei, et al.
Publicado: (2013) -
Surgical Treatment of Sacral Chordoma: The Role of Laparoscopy
por: Efetov, Sergey K., et al.
Publicado: (2020) -
Sacral and thoracic chordoma with pulmonary metastases: A case report and review of the literature
por: Bai, Rui, et al.
Publicado: (2021)